Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Table 3 Comparison of other genetic alterations between older and younger AML patients ^a

Variant	Number of patients with the gene mutation (percentage); Median of RNA expression (delta C_T)			P
Variant	Whole cohort	60 years or younger, (n=69)	Older than 60 y/o, (n=44)	P
NPM1 ^mut	38 (33.33%)	21 (30%)	17 (38.64%)	0.227
FLT3- ITD	23 (20.18%)	15 (21/43%)	8 (18.18%)	0.433
FLT3- TKD	8 (7.02%)	2 (2.86%)	6 (13.64%)	0.036*
NPM1^mut/FLT3- ITD^neg	22 (19.30%)	11(15.71%)	11 (25%)	0.164
CEBPA ^a	34 (30.36%)	18 (26.09%)	16 (37.20%)	0.151
CEBPA ^{Double mutation,b}	9 (78.04%)	8 (11.59%)	1 (2.23%)	0.016*
IDH1 ^c	3 (3.75 %)	2 (4%)	1 (3.3%)	0.686
IDH2 ^c	8 (10 %)	4 (8%)	4 (13.2%)	0.454
DNMT3A ^c	12 (15 %)	10 (25.641%)	2 (4.88%)	0.095
MLL	7 (8.75%)	4 (8%)	3 (10%)	0.528
Delta BDH2 ^d	9.006 (4.53-12.36)	9.051 (4.53-12.36)	8.915 (6.4-12.15)	0.102
ERG ^d	10.595 (4.52-19.92)	10.88 (5.17-19.92)	9.74 (4.52-19.85)	0.435
MN1 ^d	13.25 (7.75-19.87)	13.06 (7.76-19.87)	13.25 (7.75-18.38)	0.992
miR-181a ^d	3.21 (−3.8-8.44)	3.3 (−0.03-8.44)	2.49 (−3.8-8.2)	0.140
miR-3151 ^d	12.685 (4.97-15.29)	12.685 (9.16-15.07)	12.6 (4.97-15.29)	0.247

Values are number (%) of patients with alteration.
^aCEBPA^{single and double mutations}.
^bCEBPA^{double mutation}vs CEBPA^{single mutation}vs no mutation.
^cOnly 80 patients with high quality of DNA to sequence; 50 patients are 60 y/o or younger patients and 30 patients are high expression.
^dMedian delta C_T(range).
*Statistically significant (P < 0.05).

ISSN: 1423-0127